B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

Bibliographic Details
Main Authors:	P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt, A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso, K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono, M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, N. van de Donk
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000936104.91195.3e

Similar Items

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
by: N. van de Donk, et al.
Published: (2023-05-01)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
by: Stefania Oliva, et al.
Published: (2021-06-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET)
by: J. N. Nørgaard, et al.
Published: (2022-06-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
by: D. Dytfeld, et al.
Published: (2022-06-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
by: E. A. Martino, et al.
Published: (2022-06-01)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
by: Anna Astarita, et al.
Published: (2023-02-01)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
by: Yoshiyuki Onda, et al.
Published: (2022-06-01)

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
by: C. Cerchione, et al.
Published: (2022-06-01)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Published: (2023-03-01)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
by: Ja Min Byun, et al.
Published: (2020-05-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
by: Fortunato Morabito, et al.
Published: (2022-07-01)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
by: I. Attucci, et al.
Published: (2023-05-01)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Highly skilled returnees and the internationalization of EMNEs: Firm level evidence from China
by: Fu, X, et al.
Published: (2016)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
by: A. Larocca, et al.
Published: (2023-05-01)

P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR MULTIPLE MYELOMA
by: B. Derman, et al.
Published: (2022-06-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

17th Annual EMN Congress Cluj-Napoca, Romania
by: Romanian Society of Neurosurgery .
Published: (2012-06-01)

Uppsala Model: A Contingent Theory to Explain the Rise of EMNEs
by: Renan Henrique Oliveira, et al.
Published: (2018-08-01)

EURAMET EMN-Q: The European metrology network for quantum technologies
by: Ivo Pietro Degiovanni, et al.
Published: (2021-12-01)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
by: Mads Harsløf, et al.
Published: (2023-08-01)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
by: Meletios Dimopoulos, et al.
Published: (2018-04-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
by: J. Doorduijn, et al.
Published: (2022-06-01)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
by: S Morè, et al.
Published: (2022-04-01)

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)
by: M. D’Agostino, et al.
Published: (2022-06-01)

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
by: Mads Harsløf, et al.
Published: (2024-04-01)

Special Issue “The Genetic Changes Induced by Engineered Manufactured Nanomaterials (EMNs)”
by: Marta Marmiroli
Published: (2022-06-01)

P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.
by: Antonio Garcia-Guiñon, et al.
Published: (2023-08-01)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
by: Wendy B.C. Stevens, et al.
Published: (2020-02-01)

P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
by: A. Rijneveld, et al.
Published: (2022-06-01)

P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
by: R. Tilmont, et al.
Published: (2022-06-01)